This is the authors' abstract. We don't add key points for this paper.
Monotherapy with S-1 demonstrated noninferiority to gemcitabine in overall survival with good tolerability and presents a convenient oral alternative for locally advanced and metastatic pancreatic cancer.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ueno et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: